Published in Cancer Weekly, June 30th, 1997
The CA 15-3 RIA, when used in conjunction with other clinical and diagnostic methods, is a valuable adjunct in the overall management of breast cancer patients.
Developed and brought to market in other countries by Centocor since 1985, the CA 15-3 RIA is now available for use in the U.S. Through a distribution agreement with Fisher Scientific, of Houston, Texas, the CA 15-3 RIA is...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Cancer Weekly
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.